Rethinking Platform Biotech - How Emerging Innovators Are Structuring the Future of Pharma Collaboration

Our CEO Sam Windsor spoke at Fierce Pharma Biotech week 2025 in Boston.

Platform biotech companies are reshaping pharma’s innovation model - but getting deals done requires more than breakthrough science. In this session, leaders from emerging platform companies shared hard-earned lessons from the dealmaking front lines. Alongside pharma perspectives, they unpacked how they framed value, navigated control, and structured partnerships to preserve upside while building long-term credibility.

The panel discussed:

• How platform biotechs are proving value beyond a single asset—and what that means for deal design.
• How companies approach optionality, equity stakes, and governance to align short-term needs with long-term vision.
• What biotechs wish pharma understood better when it comes to platform risk, valuation, and partnership expectations.

Panelists: Sam Windsor, Hanadie Yousef, Dinesh V. Patel, and Sahm Nasseri

‍